You are here:

pegylated liposomal doxorubicin in combination with boretezomib (Caelyx plus Velcade)

Advice

Following a re-submission

pegylated liposomal doxorubicin (Caelyx) is not recommended for use within NHS Scotland in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Results from an interim analysis showed that pegylated liposomal doxorubicin plus bortezomib significantly increased the time to disease progression compared to bortezomib monotherapy. At the time of the interim analysis only 31% of patients in the combination arm had reached the primary endpoint.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: pegylated liposomal doxorubicin in combination with boretezomib (Caelyx plus Velcade)
SMC Drug ID: 503/08
Manufacturer: Schering-Plough Ltd
Indication: Progressive multiple myeloma
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 13 July 2009

Archived Advice

Full submission 13 October 2008

Back